COEPW (COEPW) — Quarterly Report

Key Insights

• The filing shows Z Squared Inc. (ticker ZSQR, not Coeptis/COEPW as mentioned in request) with multiple convertible debt instruments and warrant structures outstanding, including October 2022 convertible notes and Yorkville convertible notes, indicating potential future dilution to shareholders.
• The company maintains various intangible assets including Purple BioTech licenses, VyGen CD38 assets, and co-development rights, but the truncated filing prevents assessment of impairment charges or asset valuations for Q1 2026.
• Presence of SEPA (Standby Equity Purchase Agreement) activity through March 2026 and customer concentration risk disclosures suggest limited revenue scale with dependency on few customers and ongoing equity financing mechanisms to fund operations.
• The filing references multiple series of preferred stock and subscription receivables, indicating complex capitalization structure typical of distressed or pre-revenue biotech entities with significant financing pressures.